Juthaporn Cowan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/788858/publications.pdf

Version: 2024-02-01

1307594 1125743 22 199 7 13 citations g-index h-index papers 22 22 22 373 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	COVID-19 and post-infectious myalgic encephalomyelitis/chronic fatigue syndrome: a narrative review. Therapeutic Advances in Infectious Disease, 2021, 8, 204993612110093.	1.8	85
2	Effectiveness of immunoglobulin prophylaxis in reducing clinical complications of hematopoietic stem cell transplantation: a systematic review and metaâ€analysis. Transfusion, 2018, 58, 2437-2452.	1.6	17
3	Clinical outcomes of polyvalent immunoglobulin use in solid organ transplant recipients: A systematic review and metaâ€analysis – Part II: Nonâ€kidney transplant. Clinical Transplantation, 2019, 33, e13625.	1.6	14
4	Prevalence of Hypogammaglobulinemia in Adult Invasive Pneumococcal Disease. Clinical Infectious Diseases, 2018, 66, 564-569.	5.8	12
5	Clinical outcomes of polyvalent immunoglobulin use in solid organ transplant recipients: A systematic review and metaâ€analysis. Clinical Transplantation, 2019, 33, e13560.	1.6	11
6	A national survey of screening and management of hypogammaglobulinemia in Canadian transplantation centers. Transplant Infectious Disease, 2017, 19, e12706.	1.7	9
7	Shift in Epidemiology of Cryptococcal Infections in Ottawa with High Mortality in Non-HIV Immunocompromised Patients. Journal of Fungi (Basel, Switzerland), 2019, 5, 104.	3.5	8
8	Evaluation of a Personalized Subcutaneous Immunoglobulin Treatment Program for Neurological Patients. Canadian Journal of Neurological Sciences, 2019, 46, 38-43.	0.5	8
9	Discontinuation of immunoglobulin replacement therapy in patients with secondary antibody deficiency. Expert Review of Clinical Immunology, 2020, 16, 711-716.	3.0	7
10	A High-Throughput NanoBiT-Based Serological Assay Detects SARS-CoV-2 Seroconversion. Nanomaterials, 2021, 11, 807.	4.1	7
11	Study protocol: a randomized, double-blind, parallel, two-arm, placebo control trial investigating the feasibility and safety of immunoglobulin treatment in COPD patients for prevention of frequent recurrent exacerbations. Pilot and Feasibility Studies, 2018, 4, 135.	1.2	4
12	Polyvalent Immunoglobulin as a Potential Treatment Option for Patients with Recurrent COPD Exacerbations. International Journal of COPD, 2021, Volume 16, 545-552.	2.3	4
13	A Randomized Double-Blind Placebo-Control Feasibility Trial of Immunoglobulin Treatment for Prevention of Recurrent Acute Exacerbations of COPD. International Journal of COPD, 2021, Volume 16, 3275-3284.	2.3	4
14	Chronic obstructive pulmonary disease exacerbation frequency and serum IgG levels. Journal of Allergy and Clinical Immunology, 2018, 141, 830-831.	2.9	3
15	Differential immunomodulation of T-cells by immunoglobulin replacement therapy in primary and secondary antibody deficiency. PLoS ONE, 2019, 14, e0223861.	2.5	3
16	Immunoglobulin replacement therapy discontinuation in patients with antibody deficiency secondary to hematological malignancy. Hematological Oncology, 2021, 39, 584-588.	1.7	2
17	Evaluation of the protein gap for detection of abnormal serum gammaglobulin level: an imperfect predictor. Clinical Chemistry and Laboratory Medicine, 2021, 59, 869-874.	2.3	1
18	Toxoplasmosis, cryptosporidiosis, and isosporiasis in HIV-negative immunocompromised patients: A single-centre study, Ottawa, Ontario, Canada. Jammi, 2020, 5, 239-244.	0.5	0

#	Article	IF	CITATIONS
19	Title is missing!. , 2019, 14, e0223861.		O
20	Title is missing!. , 2019, 14, e0223861.		0
21	Title is missing!. , 2019, 14, e0223861.		O
22	Title is missing!. , 2019, 14, e0223861.		0